Marco Piva

Also affiliated with BioCruces Health research Institute, CIC bioGUNE

Biochemistry, Genetics and Molecular BiologyComputer ScienceMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy”.

Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy

Cancer Cell(2021)10.1016/j.ccell.2021.07.023

N/A

3.9DataRank · unranked

135 citations

Sixue Liu, Zhentao Yang, Alain P. Algazi, Shirley H. Lomeli, Yan Wang +16 more

Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma

UNC Libraries(2020)10.17615/73y8-rn80

N/A

0DataRank · unranked

7 citations

Gatien Moriceau, Robert Damoiseaux, Roger S. Lo, Lu Sun, Aayoung Hong +5 more

Enhancing PD-L1 Degradation by ITCH during MAPK Inhibitor Therapy Suppresses Acquired Resistance

Cancer Discovery(2022)10.1158/2159-8290.cd-21-1463

N/A

0DataRank · unranked

39 citations

Yan Wang, Sixue Liu, Weixian Deng, Shirley H. Lomeli, Gatien Moriceau +4 more